Manufacturing Late Stage and Commercial Quantities
Agilent is dedicated to current good manufacturing practices (cGMP) as defined by ICH for providing active pharmaceutical ingredients (APIs). We own two facilities equipped to serve all your oligo API needs. The 77,000 square foot cGMP facility located in Boulder, Colorado, USA, houses multiple suites enabling the manufacture of several products simultaneously. A broad range of synthesis and purification equipment allows for production for toxicology and preclinical use to late-stage clinical trials and commercial launch. Our latest 135,000 square foot cGMP facility located in Frederick, Colorado, has enabled us to more than double our clinical/commercial manufacturing capacity for nucleic acid-based therapeutics.